CMH B2B Lead at Eli Lilly and Company

Seoul, South Korea, South Korea

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, HealthcareIndustries

Requirements

Bachelor's degree; Post-graduate degree or MBA preferred
7 to 10+ years of work experience in Sales & Marketing, PRA or Finance or from outside ideally in Fast-Moving Consumer Goods, OTC Companies or PE departments
Analytics and/or forecasting experience
Strong business acumen, market understanding and ability to identify external trends
Ability to influence stakeholders at all levels. Consistent demonstration of the leadership behaviors and ability to develop credibility in a network that spans a wide variety of functions

Responsibilities

Develop & Execute a PE Market Entry & Growth Strategy: Establish a scalable go-to-market model for private-sector obesity care adoption; Map and prioritize key private-sector market segments (employers, insurers, digital health partners, clinics, …); Partner with market access teams to design novel pricing, reimbursement, and value-based engagement models; Integrate PE Market Entry & Growth with overall Commercialization strategy
Build & Expand Strategic Partnerships: Develop C-level relationships with global private payers, insurance providers, employer benefits leaders, corporate wellness platforms, retail pharmacy and telehealth networks; Drive strategic alliances that enable sustainable and scalable distribution of obesity therapies in private settings; Collaborate with distributors, pharmacy chains, and digital health providers to ensure efficient supply chain integration
Deliver High-Impact Commercial Results: Accelerate private-market adoption of obesity treatments, driving measurable revenue impact; Lead the design & execution of innovative PE engagement models (e.g., subscription-based models, tiered access programs, employer-led reimbursement schemes); Partner with marketing & sales teams to craft PE value propositions that align with external stakeholders
Shape Private Market Access & Policy Advocacy: Work with internal and external stakeholders to navigate regulatory and policy complexities; Advocate for corporate wellness incentives and insurance frameworks that enhance obesity treatment adoption; Leverage data-driven insights and health economics models to demonstrate ROI to private-sector partners

Skills

Market Entry Strategy

Go-to-Market

Partnership Development

Market Segmentation

Commercial Strategy

Reimbursement Strategy

B2B Sales

Healthcare Partnerships

Obesity Care

Private Ecosystem

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free